Tau is abundant in the axon, whereas MAP2 is found in the cell body and dendrites. To understand their differential localization, we performed transfection studies on primary cultured neurons using tagged tau, MAP2, MAP2C, and their chimeric/deletion mutants. We found that MAP2 was prevented from entering the axon by its N-terminal projection domain and that microtubule binding of tau was stronger in the axon than in the cell body and dendrites, whereas that of MAP2/ MAP2C was tighter in the cell body and dendrites than in the axon. These binding properties were determined by their microtubule-binding domains and were suggested to be regulated by phosphorylation, at least in the case of tau. Thus, the suppressed axonal transit of MAP2 and locally regulated microtubule binding may play important roles for their sorting in neurons.
Introduction
Microtubules are one of the main cytoskeletal elements in all eukaryotic cells and are particularly abundant in neuronal cells. It is well known that there are several kinds of associated proteins that regulate the structure and dynamics of microtubules. Among these proteins, tau and microtubule-associated protein 2 (MAP2) are the major species in neuronal tissues, which are flexible, rod-like structures, form arm-like projections on microtubules, and have been identified as the components of crossbridges found in the microtubule domain in neurons (Murphy and Borisy, 1975; Weingarten et al., 1975; Cleveland et al., 1977a Cleveland et al., , 1977b Kim et al., 1979; Zingsheim et al., 1979; Hirokawa, 1982 Hirokawa, , 1991 Voter and Erickson, 1982; OImsted, 1986; H irokawa et al., 1988a , 1988b . Recent cloning studies revealed that tau and MAP2 share a homologous microtubule-binding domain in their C-terminal halves ( Figure 1 ) (Aizawa et al., 1988; Lee et al., 1988; Lewis et al., 1988) , and when they are transfected into nonneuronal cells, they form bundles of microtubules that show structures very similar to those found in neurons (Kanai et al., 1989; Lewis et al., 1989; Knops et al., 1991 ; Chen et al., 1992) .
However, tau and MAP2 are found in different regions in neurons immunocytochemically; tau is abundant in the axon Kosik and Finch, 1987) , whereas MAP2 is localized in the cell body and dendrites (Bernhardt and Matus, 1984) (Figure 2 ). It is therefore of major importance to clarify the mechanism for their different Iocalizations in order to understand neural polarity. Concerning this mechanism, two possibilities have been proposed. One is that their Iocalizations are determined by where they are expressed, as tau m RNA spread into the proximal portion of axon while MAP2 m RNA extended into dendrites (Garner et al., 1988; Litman et al., 1993) . The other is that locally differing protein turnover generates their selective localization. When MAP2 was injected into neurons, it was degradated more rapidly in the axon than in the cell body and dendrites (Okabe and Hirokawa, 1989) . However, complete understanding is still to be attained.
Here, we propose new mechanisms regarding this question by transfecting primary cultured neurons with tagged cDNAs encoding tau, MAP2, MAP2C (juvenile form of MAP2), and their chimeric/deletion mutants ( Figure 1 ). MAP2 and the mutants containing its N-terminal projection domain were transported along the axon much shorter distances than others, suggesting that the N-terminal projection domain of MAP2 suppressed its axonal transit. As for their subcellular microtubule binding, tau bound to microtubules more strongly in the axon than in the cell body and dendrites, whereas MAP2/MAP2C bound to microtubules more tightly in the cell body and dendrites, and their locally selective bindings were determined by their C-terminal microtubule-binding domains. Interestingly, tau in the cell body and dendrites was mostly phosphorylated at the TAU-1 site Papasozomenos and Binder, 1987; Hasegawa et al., 1992; Szendrei et al., 1993) , suggesting that microtubule binding may be regulated by local phosphorylation/dephosphorylation, at least in the case of tau. Thus, suppressed transit of MAP2 into the axon and the locally regulated microtubule binding of tau and MAP2/MAP2C may play important roles for their differential localization in neurons.
Results

Distribution of Native Tau, MAP2, and MAP2C in Primary Cultured Spinal Cord Neurons
To investigate the distribution of native tau, MAP2, and MAP2C in primary cultured spinal cord neurons, we fixed and immunostained the cells 17 days after plating, as cells in our transfection studies were transfected 12 days after plating and then fixed 5 days later. TAU-1, a monoclonal anti-tau antibody, stained axons, whereas affinity-purified polyclonal anti-MAP2 antibody detected high molecular weight MAP2 in cell body and dendrites but not in axons (Figures 2a-2c) . Because "I'AU-1 detects only the dephosphorylated form of tau at the TAU-1 site, we treated the culture with alkaline phosphatase and stained tau with TAU-1 (see Figure 4d ) (Papasozomenos and Binder, 1987) . TAU-1 stained, though weakly, the cell body and proximal dendrites in addition to the axon, suggesting that tau phosphorylated at the TAU-1 site is localized in the cell body and proximal dendrites in smaller amounts in this stage of culture. MAP2C is an alternatively spliced isoform of MAP2 and is reported to be observed in cell MT Tau-MAP2, MAP2 Tau, and MAP2C-Tau are chimeric mutants (e.g., Tau-MAP2 contains the N-terminal projection domain of tau, fused to the C-terminal microtubule-binding domain of MAP2). Tau(N), MAP2(N), and MAP2C(N) are deletion mutants containing only their N-terminal projection domains (e.g., Tau(N) has the N-terminal domain of tau but lacks the C-terminal microtubule-binding domain). Tau(MT) and MAP2(MT) are also deletion mutants and consist of the C-terminal microtubule-binding domains (e.g., Tau(MT) contains only the C-terminal half of tau without its N-terminal projection domain). Boxed regions (three or four parts) are the repeated microtubule-binding motifs, and open and shaded portions are derived from tau and MAP2 (MAP2C), respectively. (B) Amino acid comparison between tau and MAP2 (MAP2C) in the C-terminal microtubule-binding domain, which is composed of the proline-rich region, three or four repeated domains, and the C-terminal acidic region (numbering according to rat tau [Kanai et al., 1989] and mouse MAP2 [Lewis et al., 1988] ). The percentages of identical amino acids between tau and MAP2 are 50% (proline-rich region), 63% (repeat 1), 74% (repeat 3), 63% (repeat 4), and 65% (C-terminal acidic region). The TAU-1 site is underlined in the proline-rich region (GERS-GYSSPGSPGTPG; Szendrei et al., 1993) . Note that there are several Ser(Thr) residues followed by a Pro in this microtubule-binding domain, especially in the TAU-1 site.
bodies, dendrites, and axons of developing neurons (Tucker et al., 1988a (Tucker et al., , 1988b . As an antibody against only MAP2C (which does not stain MAP2) was not available, we performed a double staining using two types of anti-MAP2 antibodies: HM-2, a monoclonal antibody that recognizes both MAP2 and MAP2C, and a polyclonal antibody that stains only MAP2 (Figure 2a) . However, the staining patterns of both antibodies showed few differences, if any (data not shown), and we could not detect MAP2C in the axon by immunofluorescence microscopy in this stage of neurons.
Construction of Tagged cDNAs Encoding Tau, MAP2, MAP2C, and Chimeric/Deletion Mutants
Although tau and MAP2 (MAP2C) consist of the N-terminal projection domain and the homologous C-terminal microtubule-binding domain, tau is abundant in the axon while MAP2 is localized in the cell body and dendrites. To study the mechanisms for their different subcellular Iocalizations in neurons, we performed a series of transfection studies into mouse primary cultured spinal cord neurons using cDNAs encoding tau (the largest isoform, 432 amino acids; Kanai et al., 1989 Kanai et al., , 1992 , MAP2 (1828 amino acids; Lewis et al., 1989) , MAP2C (juvenile type of MAP2, 467 amino acids; Papandrikopoulou et al., 1989; Umeyama et al., 1993) , and their chimeric/deletion mutants ( Figure 1 ). As neurons also express these MAPs in nature, we must distinguish the transfectants from the intrinsic MAPs. Tau and MAP2 share a homologous C-terminal microtubulebinding domain (Aizawa et al., 1988; Lee et al., 1988; Goedert et al., 1989; Kanai et al., 1989; Kosik et al., 1989; Lewis et al., 1989; Papandrikopoulou et ai., 1989) , and the C-terminal tail of tau and MAP2C has little effect on microtubule binding and bundling Umeyama et al., 1993) ; in contrast, their N-terminal projections could participate in possible antiparallel dimerization (Steiner et al., 1990; Chen et al., 1992; Kanai et al., 1992; Wille et al., 1992a Wille et al., , 1992b Wille et al., , 1992c . Therefore, we introduced a short sequence from c-myc (KLISEEDL; Evan et al., 1985; Wong and Cleveland, 1990; Meichsner et al., 1993) or c-myb (EDPEKEKRIKEL) to their C-terminal tail as a tag. As we use the antibodies against c-myc and c-myb sequences in this study, we checked these antibodies and found that they did not stain the control primary cultured spinal cord cells (data not shown). Because primary cultured spinal cord neurons grow on a sheet of glial cells, it is very important to use a high expression, neu ton-specific vector system in order to perform the transfection studies on this culture. At the time of transfection, 12 clays after plating, glial cells had become confluent, suggesting that their requirement for additional actin was low, whereas neurons might still spread their processes as if more actin proteins were necessary for them. Then, we compared the expression levels of 13-actin mRNA between neurons and glial cells by in situ hybridization, which revealed that the 13-actin expression level was very high in neurons but very low in glial cells (Figure 2d ). Therefore, we chose a ~-actin promoter, and the constructs were inserted into a I?,-actin enhancer-driven pinsmid (Xie, 1984; Kanai et al., 1989 Kanai et al., , 1992 for the following transfection experiments.
To check the microtubule-binding and -bundling abilities of the tagged MAPs, we transfected them into a mouse fibroblast cell line, L cells. They bound to and bundled microtubules like native MAPs transfected into L cells, suggesting that their microtubule-binding and -bundling abilities were intact (data not shown; Kanai et al., 1989 Kanai et al., , 1992 Lewis et al., 1989; Umeyama et al., 1993 Figure 3 ). Tau and MAP2C were stained far into the axon (tau, 878 _+ 333 i~m, n = 22; MAP2C, 600 _ 132 I~m, n = 16) as well as strongly in the cell body and dendrites (Figures 3a and 3b ). However, although MAP2 was detected strongly in the cell body and dendrites, it was found only in the short proximal segment of the axon (MAP2, 22.7 _ 31.0 I~m, n = 29; Figure 3c ). As it is very difficult to identify the axon of a MAP2-transfected neuron, and to exclude the possibility that differing expression levels between tau and MAP2 influence their axonal entries, we performed a pair of cotransfection studies using tau
(c-myc)/MAP2(c-myb) and tau(c-myb)lMAP2(c-myc) to ex-
press exogenous tau and MAP2 in the same neurons, equalizing their expression levels by changing their DNA ratio (see Experimental Procedures). In each case, tau was found far into the axon, but MAP2 was observed only in the short proximal segment of the axon (Figures 3e and 3f) .
Exogenous tau was found in the cell body and dendrites as well as in the axon. However, many studies investigating the subcellular localization of tau in neurons have been done using TAU-1, which recognizes only the unphosphorylated form of tau at the TAU-1 site (residues 191-225; Figure 1 B) but does not react with the phosphorylated tau at this site, and it was reported that TAU-l-unreactive tau was detected in the cell body and dendrites Papasozomenos and Binder, 1987; Hasegawa et al., 1992; Szendrei et al., 1993) . To investigate the phosmice, stained by the anti-MAP antibodies used in this study. TAU-1 (lane 1), a monoclonal anti-tau antibody , recognized tau. HM-2 (lane 2), a monoclonal anti-MAP2 antibody, stained both MAP2 and MAP2C. Affinity-purified rabbit anti-MAP2 antibody (lane 3) recognized only high molecular weight MAP2 but did not react with MAP2C. Monoclonal anti-MAP1B antibody (lane 4) stained high molecular weight MAP1B heavy chain. (b and c) Distribution of native MAPs in primary cultured spinal cord neurons 17 days after plating. Cells were double stained by TAU-1 (b) and polyclonal anti-MAP2 antibody (c). TAU-1 stained axons (thin neurites) but did not react with cell bodies or dendrites (thicker neurites) observed in anti-MAP2 staining. MAP2 was found in cell bodies and dendrites but not in axons. in the axon, cell body, and dendrites (Figure 4a ), whereas TAU-1 staining was strong in the axon but faint in the cell body and dendrites, similar to the native localization of tau stained by TAU-1 (Figure 2b ; Figure 4b ). Although TAU-1 also stained native tau in the axon, the staining of axons of transfected neurons was much stronger than that of untransfected neurons, meaning that this strong staining was mostly exogenous (Figures 4b and 4c) . Next, in the phosphatase treatment study, TAU-1 stained the cell body and dendrites in addition to the axon in the dephosphorylated neurons, although the staining in the cell body and dendrites was weaker than that in the axon, and it tended to be restricted to the proximal dendrites ( Figure  4d ). These data indicated that exogenous tau showed similar distribution to native tau in neurons.
Microtubule Binding of Tau Was Stronger in the Axon, whereas That of MAP2 Was Tighter in the Cell Body and Dendrites
To examine the possible involvement of locally differing microtubule binding affinities of these MAPs on their differential Iocalizations, we permeabilized the cells in a microtubule-stabilizing buffer before fixation to remove the soluble proteins ( Figure 5 ). Tau remained in the axon in the extraction condition in which most of tau in the cell body and dendrites disappeared (Figure 5a ). By the same procedure, however, MAP2C, which was also transported a sizeable distance along the axon, mostly disappeared from the axon, while remaining in the cell body and dendrites like MAP2 (Figures 5b and 5c ). This indicated that tau bound to microtubules more strongly in the axon than in the cell body or dendrites, whereas MAP2/MAP2C bound to microtubules more tightly in the cell body and dendrites than in the axon. (a) stained all the exogenous tau, and the staining was prominent in the cell body and dendrites as well as in the axon. In contrast, TAU-1 (b) stained the axon strongly, but the cell body and dendrites were stained very weakly. (c) shows the same picture as (b) but was printed differently in order to observe native tau in untransfected axons. Although TAU-1 stained both native and transfected axons, transfected axons were stained much stronger than native ones, suggesting that the strong staining of axons in the transfected neurons was mostly exogenous.
(d) TAU-1 staining of primary cultured neurons after phosphatase treatment. TAU-1 recognized the cell bodies and dendrites in addition to axons in the phosphatase-treated neurons, although the staining in the cell body and dendrites is weaker than that in the axon. As TAU-1 does not recognize phosphorylated tau at the TAU-1 site (Papasozomenos and Binder, 1987) , most of the intrinsic and exogenous tau may be phosphorylated at this site in the cell body and dendrites. Bar, 50 ~m. 
Domain Functions of Tau, MAP2, and MAP2C for Subcellular Sorting
These studies using full-length MAPs revealed that axonal entry of MAP2 was less in length than that of tau or MAP2C, and that microtubule binding of tau was stronger in the axon than in the cell body and dendrites, whereas the binding of MAP2/MAP2C was tighter in the cell body and dendrites than in the axon. To study further the domain functions of these MAPs for their different subcellular distribution and microtubule binding, we performed a series of transfection studies using chimeric/deletion mutants ( Figure 1 ; Table 1 ; Figure 6 ; Figure 7 ). Tau-MAP2, MAP2-Tau, and MAP2C-Tau are chimeric mutants (e.g., Tau Figures 6a and 6b) . On the other hand, tau, MAP2C, and the mutants that did not have the N-terminal half of MAP2 were transported far into axons, with no significant differences in the stained length among them (600-900 tim; Table 1; Figure 6c ). To exclude the possibility that the N-terminal projection domain of MAP2 suppressed its entry into axons only because of its long molecular size, we investigated the localization of intrinsic MAP1B heavy chain, which is larger in molecular weight and longer in molecula'r structure, and found it in the axon, cell body, and dendrites (Figure 6d ), as previously reported (Sato-Yoshitake et al., 1989) .
Next, to investigate the domains for their regionally selective microtubule binding, cells were permeabilized before fixation. Tau and the mutants containing the C-terminal microtubule-binding half of tau (MAP2-tau, MAP2C-tau, and tau(MT)) remained in the axon, whereas MAP2, MAP2C, and the mutants with the C-terminal domain of MAP2 (tau-MAP2 and MAP2(MT)) were found in the cell body and dendrites, but tended to disappear from axon. The mutants lacking the microtubule-binding domain (tau(N), MAP2(N), and MAP2C(N)) disappeared from the transfected cells (Table 1 ; Figure 7 ).
Discussion
J~-Actin Promoter May Work as a High Expression and Neuron-Selective Promoter in Primary Cultured Spinal Cord Cells
In situ hybridization studies suggested that the ~-actin promoter was highly activated in neurons but was suppressed in glial cells in the primary cultured spinal cord ( Figure  2d ). Indeed, this promoter showed a high level, neurondominant expression pattern in our transfection experiments. This study indicated that transfection using I~-actin enhancer-driven plasmid into primary cultured spinal cord neurons may be a useful and powerful tool to introduce cDNAs into cultured neurons. 
Transfected Tagged MAP2 and Tau Showed Similar Localizations to Native MAPs in Neurons
Tau is abundant in the axon, whereas MAP2 is localized in the cell body and dendrites. MAP2C is observed in the cell body, dendrites, and axon of a developing neuron. As we used a transfection method using the constructs encoding MAPs and their mutants fused with a tag sequence in their C-terminal end to investigate their sorting mechanisms, it is necessary to examine the extent of their effects on the subcellular localization of exogenous MAPs. Tagged MAP2 showed distribution similar to that of native MAP2; MAP2 was observed in the cell body and dendrites but was found only in the short proximal segment of the axon. In the case of MAP2C, although exogenous MAP2C was found in the cell bodies, dendrites, and axons, native MAP2C was not detected in axons by immunofluorescence microscopy ( Figure 3) . As for tau, although exogenous tau was detected in the cell body and dendrites as well as in the axon by anti-tag antibody, its TAU-1 staining was axon-dominant and disappeared almost completely from the cell body and dendrites (Figures 4a-4c) . In addition, the phosphatase treatment study revealed that TAU-1 also stained the cell body and dendrites in dephosphorylated primary cultured neurons, although the staining in the cell body and dendrites was much weaker than that in the axon (Figure 4d ). Considering the fact that many of the studies on tau were performed using TAU-1 and that TAU-l-unreactive tau is observed in the cell body and dendrites (Papasozomenos and Binder, 1987) , we think that exogenous tau showed a distribution similar to that of native tau in neurons, although the amount of exogenous tau in the cell body and dendrites relative to that in the axon is somewhat higher than it is with native tau. As for the distribution of exogenous MAP2C in the axon and tau in the cell body and dendrites, we think that it may be due to the higher amount of expression of these MAPs. Indeed, in neurons at an early developmental stage, when their expression levels are higher, MAP2C is reported to be found in the cell body, dendrites, and axon (Tucker et al., 1988a) . Thus, we believe that the inserted sequence and the overexpression by transfection did not change their physiological distributions significantly.
N-Terminal Projection Domain of MAP2 Interferes with Its Axonal Transit
As for the axonal distribution of transfected MAPs, tau and MAP2C were found far into the axon (-900 I~m), whereas MAP2 was observed only in the short proximal segment (-23 ~m; Figure 3 ). To investigate this differing axonal transit among these MAPs, we performed mutant studies and showed that the mutants, MAP2-tau and MAP2(N), containing the long N-terminal projection domain of MAP2, were found to be transported a lesser length in axons (-200 i~m) than the others (-900 I~m). This suggests that the N-terminal projection domain of MAP2, especially the inserted region lacking in MAP2C, suppressed its axonal transit in neurons. The axonal distribution of MAP1 B heavy chain, a larger molecule than MAP2, indicated that this inhibition may not be due only to its larger protein size (Table 1 ; Figure 6 ). However, considering the fact that MAP2 was transported along the axon a much shorter distance (23 I~m) than MAP2-tau or MAP2(N) (-200 I~m) and that MAP2 bound to microtubules more tightly than MAP2-tau or MAP2(N) in the cell body and dendrites, other mechanisms (e.g., locally selective microtubule binding) may also keep MAP2 within the cell body and dendrites, preventing its entry into the axon, in addition to the suppression of axonal transit by MAP2's N-terminal projection domain.
Microtubule-Binding Domains of Tau and MAP2 Determine Their Locally Selective Microtubule-Binding Abilities
Tau and MAP2/MAP2C share a homologous microtubulebinding domain (Figure 1 ) (Aizawa et al., 1988; Lee et al., 1988; Goedert et al., 1989; Kanai et al., 1989; Kosik et al., 1989; Lewis et al., 1989; Papandrikopoulou et al., 1989) , and they compete with each other in microtubule binding in vitro (Kim et al., 1986) . in vivo studies using nonneuronal cells also revealed that Sf9 cells cotransfected with tau and MAP2 projected one or more processes, but both MAPs were colocalized in the cell body and in the processes (Chen et al., unpublished data) . These data suggest that tau binds to microtubules just like MAP2/MAP2C in vitro and in vivo. However, their microtubule-binding properties were quite different in neurons; tau bound to microtubules more strongly in the axon than in the cell body and dendrites, whereas MAP2/ MAP2C bound to microtubules more tightly in the cell body and dendrites than in the axon, and these region-selective bindings were determined by their C-terminal microtubulebinding regions ( Figure 5 ; Table 1 ; Figure 7 ). This suggests that microheterogeneity in the microtubule-binding domain between tau and MAP2 (Figure 1 B) determines their locally differing binding properties in neurons, and we think that this region-selective microtubule binding could determine their locally differing turnover rates (Okabe and Hirekawa, 1989; Hirokawa et al., unpublished data) and may work as one of the sorting mechanisms for these MAP&
Microtubule Binding of Tau May Be Regulated by Locally Selective Phosphorylation
What regulates the locally differing microtubule bindings of tau and MAP2/MAP2C? Our data suggest that phosphorylation may be involved in this mechanism, as transfected tau in the cell body and dendrites was mostly phosphorylated at the TAU-1 site, but not in the axon (Fig-C phosphorylated at Ser(Thr) residues followed by Pro than adult tau (Geedert et al., 1993; Watanabe et al., 1993) . In addition, in vitro studies revealed that several prolinedirected kinases (e.g., cdc2 kinase, tau protein kinases, MAP kinase, and MAP2 kinase) phosphorylate tau into a TAU-l-unreactive form, which is reduced in microtubule polymerization and binding (Ishiguro et al., 1991; Drewes et al., 1992; Gustke et al., 1992; Ishiguro et al., 1992a Ishiguro et al., , 1992b Ledesma et al., 1992; Vulliet et al., 1992; Arioka et al., 1993; Lu et al., 1993; Scott et al., 1993) . Thus, it is possible that the selective binding of tau to axonal microtubules may be regulated by phosphorylation, which contributes to its axonal accumulation; once tau is expressed in the cell body, it is phosphorylated (TAU-l-unreactive form) and reduced in its microtubule-binding ability. Phosphorylated tau in the cell body and dendrites can be loaded on the transport system into the axon, where tau is dephosphorylated and can bind to microtubules more tightly (TAU-l-reactive form). ure 4). The TAU-1 site contains several Ser(Thr)Pro motifs (Kosik et al., 1988; Biernat et al., 1992; Szendrei et al., 1993) , and juvenile tau, which is often found in the cell body and dendrites as well as in the axon, is much more
Proline-Directed Kinase(s) May Regulate Protein Behavior in the Axon versus the Cell Body and Dendrites in Neurons
Although proline-directed protein phosphorylation is relevant to the somatic cell cycle, its function in cells of differentiated states is not well known (Hall and Vulliet, 1991; Plech and Sanghera, 1992) . Considering the transfected tau as the substrate for proline-directed kinases, the balance between kinase and phosphatase activities may be kinase-dominant in the cell body and dendrites but phosphatase-dominant in the axon. Besides the regulation of tau in microtubule binding by phosphorylation, adequate phosphorylation is necessary for MAP2 to bind to microtubules (Brugg and Matus, 1991) , and there is a report that proline-directed kinases can be involved in this phosphorylation as well (Roll et al., 1993, Am. Soc. Cell Biol., abstract) . These results suggest that proline-directed kinase may play an important role for the neuronal polarity. MAP2 and MAP2C may also be regulated by proline-directed phosphorylation in neurons, although its effects on microtubule binding are quite opposite; MAP2 and MAP2C are phosphorylated in the cell body and dendrites to bind to microtubules more tightly, but they are reduced if they are dephosphorylated in axons.
Sorting Mechanisms of Tau and MAP2 in Neurons
The mechanisms underlying the sorting of tau and MAP2 in neurons are likely to be complex. The present study clearly showed the decreased transit of MAP2 into the axon caused by its N-terminal projection domain. This result seemingly contradicts our previous microinjection study of biotinylated MAP2 into cultured motor neurons, which demonstrated that microinjected biotin-MAP2 was transported along the axon for a certain distance (Okabe and Hirokawa, 1989) . However, other studies have shown that, biochemically, MAP2 exists in white matter, although in lesser amounts (Vallee, 1982) , immunocytochemically, MAP2 is localized in small amounts in the ax0n (Hirokawa etal., 1985; Papasozomenos et al., 1985) , and our unpub-lished im m unoblot f nd ngs revealed the existence of small amounts of MAP2 in peripheral nerves (Hirokawa et al., unpublished data) . Therefore, it is reasonable to conclude that MAP2 is actually transported into axons in vivo, although the amount is small compared with other MAPs such as tau. One of the reasons for the transport of a lesser amount of MAP2 is due to the suppression of MAP2 entry into axon by its N-terminal projection domain, as shown in this study. In addition, the rapid turnover of MAP2 in the axon, demonstrated in our previous microinjection study, could also contribute to the lesser existence of MAP2 in axon (Okabe and Hirokawa, 1989) . However, based on previous studies and the present results, it is reasonable to conclude that there may be several mechanisms that cause the selective localization of tau in the axon and MAP2 in the dendrites in vivo. First is the extended localization of mRNA encoding MAP2 in the dendrites (Garner et al., 1988) and mRNA encoding tau in the initial portion of the axon (Litman et al., 1993) , second is the locally differing microtubule-binding affinities of MAP2 and tau (Okabe and Hirokawa, 1989; Hirokawa et al., unpublished data and present study) , third is the selective stabilization of MAP2 in dendrites (Okabe and Hirokawa, 1989) and tau in the axon (Hirokawa et al., unpublished data) , and fourth is the decreased transit of MAP2 into the axon (present study). These different mechanisms in concert could contribute to the final selective localization of MAP2 and tau. How the projection domain of MAP2 influences the mechanisms remains to be determined.
Experimental Procedures' Antibodies
Mouse monoclonal anti-c-myc antibody (Mycl-9E10; Evan et al, 1985; Wong and Cleveland, 1990 ) and sheep polyclonal anti-c-myb antibody were from Cambridge Res, Biochem. Ltd. (England). TAU-1, a mouse monoclonal antibody against tau, was from Boehringer Mannheim (Germany; Binderet aL, 1985) . Mouse monoclonal anti-MAP2 antibody (HM-2) was purchased from Sigma Chem. Co., and affinity-purified polyclonal anti-MAP2 antibody (Hirokawa et al., 1988a ) was a generous gift from Dr; Y. Ihara (Tokyo Univ.). Mouse monoclonal anti-MAP1 B antibody was previously described (Sato-Yoshitake et al., 1989). Rhodamine-conjugated goat anti-mouse IgG, fluorescein-conjugated goat anti-rabbit IgG, and fluorescein-conjugated donkey anti-sheep IgG were from Chemicon International, Inc. All antibodies were diluted 1 : 100 in an antibody buffer.
Immunoblot
Postnatal 0 day (P0) mouse brains were homogenized in buffer A (100 mM PIPES, 1 mM MgCI2, 1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride, 10 pm/ml leupeptin). The homogenate was centrifuged at 10,000 x gfor90 minat2'°C.SDS-polyacrylamidegelelectrophoresis (SDS-PAGE) of the "resulting crude homogenate was carried out on a 7.5% gel according to the method of Laemmli (1970) . The bands were electrophoretically transferred to nitrocellulose paper, and immunoblot was performed by the standard procedu[e.
Cell Culture
Spinal cord neurons werecultured according to the method of Ransom et al. (1977) with slight modifications. Spinal cords were taken from 12-to 14-day-old mouse embryos, treated with 0.1% trypsin for 15 rnin at 37°C, and idissociated by repeated passage through a pipette. The cell suspehsi()ns were plated onto polylysine-treated coverslips and maintained in Dulbecco's modified Eagle's medium supplemented with 5% (vol/vol) precolostrum newborn calf serum (MitsubJshi Chemical Industries, Tokyo) and 5% (vol/vol) horse serum (GIBCO).
RNA Probes for In Situ Hybridization
The mouse ~-actin probe clone pSPMbA-3'ut, kindly provided by Dr. S. Sakiyama (Tokunaga et al., 1986) , contains the sequence encoding the 3' noncoding region of ~-actin cDNA (about 80 bp) in a pGEM-1 vector. Digoxygenin-labeled single-strand RNA probes in the antisense or sense orientation were synthesized from linearized templates using the appropriate bacterial polymerase (Sp6 or T7 RNA polymerases) in the presence of digoxygenin UTP (Boehringer Mannheim) as described by the manufacturer.
In Situ Hybridization
Cells grown on coverslips were fixed for 20 rain by 2% paraformaldehyde, 0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), and then incubated successively in 0.3% Triton X-100 in phosphatebuffered saline (PBS) for 5 min, in 0.2 M HCI for 20 min, in 20 p.g/ml proteinase K (Sigma) in 50 mM Tris (pH 7.5) containing 2 mM CaCI2 for 10 min, in 4% paraformaldehyde in PBS for 5 rain, twice in 0.2% glycine in PBS for 30 min, and in 50% formamide in 2 x SSC for 1 hr. Hybridization was carried out overnight at 42°C in hybridization buffer (0.1 mg/ml salmon sperm DNA, 0.2 mg/ml tRNA, 10% dextransulfate, 50% formamide, 5x SSC, 1 x Denhardt's solution, 100 ~g/ ml heparin, 10 mM dithiothreitol) containing RNA probe. Cells were washed in 4× SSC at 42°C for 20 min and in R buffer (10 mM Tris [pH 7.5], 0.5 M NaCI) at 37°C for 15 rain and then treated with RNase A (20 i~g/ml) in R buffer at 37°C for 45 min. Cells were washed twice in R buffer for 15 rain, in 2 x SSC at 50°C for 1 hr, and twice in 0.1 x SSC at 50°C for 1 hr. Cells were incubated for 30 rain at 37°C with anti-digoxygenin antibody (conjugated to alkaline phosphatase) diluted 1:1000 (Boehringer Mannheim). At the end of the reaction, cells were washed three times for 15 rain each at room temperature with PBS, equilibrated for 5 rain in buffer containing 100 mM Tris (pH 9.5), 100 mM NaCI, and 50 mM MgCI2, and developed with nitroblue tetrazolium-bromochloroindolyl phosphate solution (0.34 mg/ml nitroblue tetrazolium and 0.175 mg/ml bromochloroindolyl phosphate in the same buffer) at room temperature.
Construction of Tagged MAPs and Their Mutants
For making the chimeric/deletion mutants, we determined the border between the N-terminal projection domain and the C-terminal microtubule-binding half at the 162nd residue of tau, as the following sequence (162-369) is necessary for tau to bind to microtubules in vivo . Since tau has a BamHI site at this residue, another BamHI site was introduced to the corresponding residue in MAP2 (1586) or MAP2C (225) to make chimeric mutants. MAP2 cDNA was a generous gift from N. J. Cowan (New York Univ.). A short sequence from c-myc (KLISEEDL) or c-myb (EDPEKEKRIKEL) was fused to the C-terminal tail of full-length MAPs and their mutants as a tag. The addition of tags, making of deletion mutants, and introduction of BamHI sites were performed by polymerase chain reaction (PCR). All the PCR fragments were sequenced and then inserted into a 13-actin enhancer-driven plasmid for the transfection studies.
Transfection
The constructs we re transfected into primary cultu red neurons 12 days after plat!ng by the standard calcium phosphate technique (Xie, 1984; Kanai et al., 1989 Kanai et al., , 1992 . A 0.5 ml calcium phosphate precipitate suspension containing 1 I~g of expression construct was added to a 3.5 cm dish incubated with primary cultured neurons. After 4 hr, the culture was fed fresh medium, and after certain periods, the culture was prepared for observation by light microscopy. The transfection efficiency was about 2%-5%.
Immunofluorescence
Cells were fixed for 15 rain at 37°C with 2% paraformaldehyde, 0.1% glutaraldehyde in PEM buffer (S0 mM PIPES, 1 mM MgCI2, 1 mM EGTA) directly or in a microtubule-stabilizing buffer (80 mM PIPES, 1 mM MgCI2, 1 mM EGTA, 10 pM Taxol, 1 mM GTP [pH 6.6]) after extraction for 2 rain at 37°C with 0.2% Triton ×-100 in the same buffer.
Cells were then permeabilized with 1% Triton X-100 in PBS and treated with 1 mg/ml NaBH, in PBS to quench the glutaraldehyde. In the phosphatase treatment study, cells were incubated with 20 U/ml calf intestine alkaline phosphatase (TOYOBO, Japan) in alkaline phosphatase buffer (50 mM Tris; pH 8.0) at 37°C for 2 hr (Papasozomenos and Binder, 1987; Kanai et al., 1989) .
The cells were reacted sequentially with a monoclonal anti-c-myc antibody alone or together with a polyclonal anti-c-myb antibody for the first antibodies, and rhodamine-conjugated goat anti-mouse IgG alone or together with fluorescein-conjugated donkey anti-sheep IgG for the second antibodies. The cells were examined with a Zeiss Axlephoto 14 epifluorescence microscope.
To equalize the expression levels of tau and MAP2 in the cotransfection studies, we determined the cDNA ratio of tau to MAP2 by doing pairs of cotransfections: tau(c-myc)lMAP2 (Figures 3e and 3f) . Their immunofluorescence intensities were monitored with an image processor (ARGUS-100; Hamamatsu Photonics, Shizuoka, Japan; Kanai et al., 1992) . When the intensity ratios of c-myc to c-myb were the same between the pair, the expressed amount of tau was equal to that of MAP2.
